This study is looking at how an artificial pancreas (AP) system, specifically the Tandem t:slim X2 with Control-IQ Technology and Dexcom G6 CGM, might improve heart health in people with type 1 diabetes. An AP system helps manage blood sugar levels by connecting an insulin pump and a continuous glucose monitor (CGM). Researchers want to see if better blood sugar control from the AP system can reduce inflammation and improve how your heart and blood vessels work. You might be able to join if you are 18-40 years old, have had type 1 diabetes for at least a year, and meet certain health criteria like an A1c below 10.5%. The main goal is to see how much time participants spend with their blood sugar in a healthy range after 12 weeks. The study is currently unclear on its recruitment status and plans to enroll 40 participants.

Study design

This is an interventional study that will randomly assign 40 participants to one of two groups for 12 weeks: one using the artificial pancreas technology and one continuing their usual diabetes care with a study CGM.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 12 weeks, indicating the duration of the main study period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.